<DOC>
	<DOCNO>NCT00842621</DOCNO>
	<brief_summary>In prospective observational trial , participant chronic hemolysis assess echocardiogram elevate tricuspid jet velocity evidence pulmonary hypertension . Participants laboratory study evaluate : severity hemolysis , splenic function , inflammation , endothelial dysfunction , hypercoagulability . There 3 main category participant enrol study : ( 1 ) pediatric participant severe sickle cell disease ( SCD ) ( HbSS , HbS/β° thalassemia ) receive treatment ( e.g. , hydroxyurea chronic transfusion ) ; ( 2 ) pediatric participant form SCD severe SCD ( HbSS , HbS/β° thalassemia ) patient treat hydroxyurea chronic transfusion ; ( 3 ) pediatric adult participant non-sickling hematological disorder .</brief_summary>
	<brief_title>Long Term Effects Erythrocyte Lysis</brief_title>
	<detailed_description>1 . The study investigate relationship tricuspid regurgitation jet velocity ( TRV ) intravascular hemolysis , measure serum lactate dehydrogenase ( LDH ) , untreated child severe sickle cell disease ( HbSS Hb S/β°-thalassemia ) 2 . The Study estimate prevalence elevate TRV ( ≥ 2.5 m/s ) untreated child severe sickle cell disease ( HbSS Hb S/β°-thalassemia ) , measure echocardiography . Secondary objective study include follow : 1 . To estimate prevalence elevate TRV child severe sickle cell disease ( HbSS Hb S/β°-thalassemia ) receive hydroxyurea chronic transfusion therapy . 2 . To estimate prevalence elevate TRV child form hemolytic anemia , include sickling disorder ( HbSC HbS/β+-thalassemia ) non-sickling hemolytic anemia ( hereditary spherocytosis ) . 3 . To estimate prevalence elevate TRV adult non-sickling hemolytic anemia , without splenic function . 4 . To investigate association TRV splenic function 5 . To investigate association TRV laboratory parameter inflammation hypercoagulability , white blood cell count , platelet count , serum N-terminal pro-brain natriuretic peptide ( NT-proBNP ) , endothelial dysfunction , marker hemolysis ( bilirubin , plasma free hemoglobin , haptoglobin , etc . ) 6 . To evaluate genetic determinant elevate TRV child adult hemolytic anemia . 7 . To investigate change TRV hemolysis time use serial measurement 2 ± 0.5 year initial enrollment testing .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Anemia , Hemolytic</mesh_term>
	<criteria>1 . Established Diagnosis Hemolysis Sickle Cell Disease ( e.g. , HbSS , HbS/βthalassemia , HbSC ) Other condition hemolysis ( e.g. , RBC membranopathies , enzymopathies , unstable hemoglobinopathy , PNH ) 2 . Age SCD participant : 5 year age 19th birthday All participant : 5 year age ( age limit ) 1 . Previous cardiac surgery 2 . Known left ventricle dysfunction ( i.e . shorten fraction &lt; 28 % ) 3 . Known right side congenital heart defect atrial septal defect pulmonary valve stenosis</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Sickle Cell Disease , Hemolytic Anemia</keyword>
	<keyword>Hemolysis</keyword>
</DOC>